NeuroPace to Participate in Upcoming Investor Conferences
- Wells Fargo 2023 Healthcare Conference -
- Morgan Stanley 21st Annual Global Healthcare Conference -
- Lake Street Capital Markets 7th Annual Best Ideas Growth Conference -
MOUNTAIN VIEW, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced its participation in the following upcoming investor conferences:
- Management will host 1x1 meetings at the Wells Fargo 2023 Healthcare Conference on Thursday, September 7, 2023, in Everett, MA.
- Joel Becker, CEO, and Rebecca Kuhn, CFO, will participate in a fireside chat discussion and host 1x1 meetings at the Morgan Stanley 21st Annual Global Healthcare Conference at 9:30 AM ET on Wednesday, September 13, 2023, in New York, NY.
- Management will host 1x1 meetings at the Lake Street Capital Markets 7th Annual Best Ideas Growth Conference on Thursday, September 14, 2023, in New York, NY
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
